Acumen Pharmaceuticals, Inc.
ABOS
$2.99
-$0.18-5.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 27.81M | 16.48M | -63.83M | 21.97M | 37.13M |
| Gross Profit | -27.81M | -16.48M | 63.83M | -21.97M | -37.13M |
| SG&A Expenses | 4.75M | 4.67M | 4.67M | 4.55M | 4.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.56M | 21.15M | 25.20M | 26.51M | 41.75M |
| Operating Income | -32.56M | -21.15M | -25.20M | -26.51M | -41.75M |
| Income Before Tax | -32.72M | -20.74M | -25.14M | -26.45M | -40.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.72M | -20.74M | -25.14M | -26.45M | -40.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.72M | -20.74M | -25.14M | -26.45M | -40.95M |
| EBIT | -32.56M | -21.15M | -25.20M | -26.51M | -41.75M |
| EBITDA | -32.55M | -21.14M | -25.19M | -26.50M | -41.73M |
| EPS Basic | -0.45 | -0.33 | -0.42 | -0.44 | -0.68 |
| Normalized Basic EPS | -0.28 | -0.21 | -0.26 | -0.27 | -0.42 |
| EPS Diluted | -0.45 | -0.33 | -0.42 | -0.44 | -0.68 |
| Normalized Diluted EPS | -0.28 | -0.21 | -0.26 | -0.27 | -0.42 |
| Average Basic Shares Outstanding | 72.25M | 63.22M | 60.57M | 60.57M | 60.57M |
| Average Diluted Shares Outstanding | 72.25M | 63.22M | 60.57M | 60.57M | 60.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |